SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Biodesy, Inc., the next-generation protein analysis company, today announced that Dominique Bridon, PhD, has been appointed Chief Executive Officer and a member of the board of directors, effective immediately.
Dr. Bridon brings more than 27 years of executive and scientific leadership experience to the Biodesy team. Most recently, he was Chief Development Officer at Nuritas, driving a disruptive approach to Peptide Discovery. Prior to that role, Dr. Bridon led the development of novel transporter-mediated oncology and CNS drugs at Optivia. He also held various leadership positions at Ipsen, Conjuchem, Redcell, and Abbott. Dr. Bridon has served as a Director for Enobia (acquired by Alexion) and Neuronax and a member of the Scientific Advisory Board of Syntaxin (acquired by Ipsen) and Biosortia.
“This is a truly exciting opportunity to lead a talented team dedicated to fundamentally improving drug discovery and transforming protein analysis for scientists around the world. The core protein conformational measurement capabilities in the Delta System directly and dynamically deliver critical structural and functional information previously unavailable in the market,” said Dr. Bridon. “I look forward to working with Executive Chairman, Joe Victor, and the entire Biodesy team to accelerate the company’s growth and ensure long-term success.”
Dr. Bridon will be located at the Biodesy headquarters in South San Francisco, Calif. He holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. He completed his Post-Doctoral Research at the University of California, Berkeley.
For more information about Biodesy and the Delta System, please visit www.biodesy.com.
About Biodesy, Inc.
Biodesy is developing the first products
and systems to rapidly measure both protein structure and function in
real time and high-throughput with applications including drug
discovery, structural biology and clinical biomarkers. Biodesy has
developed a unique and highly sensitive technology for detecting
conformational change in proteins and other biological molecules. Based
on a phenomenon called second-harmonic generation (SHG), the proprietary
technology can monitor structural changes at any site within a protein,
in real time. Since protein function is determined by its structure, and
changes in structure cause changes in function, characterizing these
changes will provide significant insights into human disease and how to
treat it. Biodesy is located in South San Francisco, California. For
more information about Biodesy and the Delta System, please visit www.biodesy.com.
The Biodesy Delta System is for Research Use Only and not for use in diagnostic procedures.
Biodesy and the Biodesy logo are trademarks of Biodesy, Inc. All other brands may be trademarks of their respective holders.
